Operand Raises $31M at $220M for Seller-Free Deal Diligence

Operand's pitch sits at a specific pain point in buyout work: the period before a seller hands over full data. The company says its agents analyze public traces, customer overlap and market positioning to reconstruct a business, and the funding write-up names Clearlake Capital as one private equity firm the technology enables to perform due diligence and turnarounds. That framing — diligence without relying on seller cooperation — is what the new capital is meant to scale, alongside expanding operations.

The same funding round carried a second, separate bet on AI that reads documents. Charta Health announced a $55 million Series B led by Insight Partners on Nov. 10, bringing its total funding to $85 million and marking its third round in less than two years. Charta's platform is built for billing accuracy: it reads clinical documentation the way an expert coder and auditor would, flagging missing codes the chart supports and removing those the documentation doesn't adequately support. Its release cites a 2025 study estimating claims adjudication cost hospitals and health systems more than $25 billion in 2023, with nearly $18 billion potentially wasted on a cycle of denials and appeals — a cycle the release says has worsened as both insurers and providers adopt AI tools that generate more denials and appeals.

Both companies describe what their platforms are designed to do, and Charta's tenfold revenue growth over the last 12 months comes from its own press release. The pairing is less about a shared technology than a shared customer pattern: firms paying for AI that reads the paperwork and returns a judgment before a deal closes or a claim goes out.